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Abstract
Background: We previously demonstrated that hsa-miR-520d-5p can convert cancer cells into induced pluripotent
stem cells (iPSCs) or mesenchymal stem cells (MSCs) via a demethylation process and p53 upregulation in vivo.
Additionally, we have reported the non-tumorigenic effect of miR-520d-5p on normal human cells, including
fibroblasts.
Methods: We used atelocollagen-conjugated miR-520d-5p (520d/atelocollagen) to confirm the possibility of
a therapeutic effect on cancer cells. We traced the size and signal intensity of GFP-expressing tumors in mice
each week, beginning 4 weeks after subcutaneous inoculation.
Results: 520d/atelocollagen treatment suppressed tumor growth by greater than 80 % each week relative to
controls and resulted in an approximately 30 % disappearance of tumors. In mice whose tumors disappeared,
the existence of human genomic material at the injection site was examined by quantitative Alu-PCR, and we
confirmed the co-existence of both species-derived cells. In every site where a tumor disappeared in
immunodeficient mice, GFP protein was expressed in the connective tissues, and approximately 0.1 % of the
extracted DNA contained human genomic material. We could not identify any adverse effects in vivo.
Conclusions: This is the first report to confirm an inhibitory effect of 520d/atelocollagen on cancer cells in vivo.
The development of optimized modifications of this carrier is expected to enhance the efficiency of entry into
tumor cells and the induction of its inhibitory effect.
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Background
Mature miRNAs are endogenous, small, noncoding
RNA (ncRNA) molecules that are 18 to 23 nucleotides
in length and transcribed by RNA polymerase II. Mature
miRNAs function as post-transcriptional gene regulators,
controlling gene expression in many cellular processes
[1, 2] or mediating cellular differentiation, reprogram-
ming and the initiation and progression of human cancer
[3–5]. Alterations in miRNA expression levels influence
tumor growth by modulating the functional expression of
target genes that are implicated in the regulation of tumor
cell apoptosis or proliferation [6]. The central role of
miRNAs during tumorigenesis has been investigated
in different tumor types, including melanomas, hepatomas,
brain tumors, and breast tumors [7–9].
We previously identified an RNA gene (RGM249) that
may indirectly regulate human telomerase reverse tran-
scriptase (hTERT) expression in undifferentiated cancer
cell lines via the induction of double-stranded (ds), small
interfering (si), and short hairpin (sh) RNAs. RGM249 is
implicated in the regulation of cell development, cell
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differentiation, anti-inflammatory effects, and cell growth
in undifferentiated cancers [10]. Our previous report dem-
onstrated that siRNAs against three small RNAs derived
from ncRNA in vivo affected the metastatic or prolifera-
tive abilities of cells during in vivo tumor growth [11].
RNA-based therapeutics for cancer have been developed.
For example, viral vectors, non-viral reagents, and nano-
particles have been pre-clinically and clinically tested to
overcome their shortcomings, such as instability in vivo
and inefficient and inaccurate targeting of organs or tumor
tissues [12–18].
We have also reported on the safety, efficacy, and spe-
cificity of drug delivery systems (DDSs) using gelatin
hydrogel microspheres or atelocollagen for subcutaneous
(s.c.) injection and spermine-pullulan or atelocollagen
for intravenous administration [19–23]. We therefore
aimed to elucidate the physiological functions of miRNA-
like molecules generated from RGM249 and their roles in
carcinogenesis, differentiation, and pluripotency. We also
investigated their potential utility for antitumor therapy or
regenerative medicine in vivo.
Targeting by miRNAs is accomplished via base-pair in-
teractions between the 5′ end of miRNAs and sites
within the coding and/or untranslated regions (UTRs) of
gene transcripts; target sites in the 3′ UTR lead to more
effective translational dysfunction [24, 25]. Because a
specific miRNA generally targets at least hundreds of
different mRNAs, it is extremely difficult to elucidate
miRNA regulatory pathways [26]. In the case of miR-
520d-5p, which can convert undifferentiated hepatoma
cells (HLF) to a benign or normal status in vivo [27],
available bioinformatics predict that it has greater than
8000 target genes. Because miR-520d-5p did not appear
to have any toxic effects on normal cells or cancer cells
and did not induce tumorigenicity or malignant transfor-
mations in vivo [28], we examined the therapeutic
effects of 520d-5p conjugated with atelocollagen as a
drug delivery system (DDS) carrier on undifferentiated
cancer cells using in vivo imaging.
Methods
Atelocollagen
Atelocollagen is a highly purified type I collagen of
the calf dermis treated with pepsin (Koken Co., Ld,
Tokyo, Japan).
RNA preparation
Synthetic 20-nt RNAs were purchased from Koken
(Tokyo, Japan) in deprotected, desalted and annealed
form. The sequence of our prepared hsa-miR-520d-5p
was 5′-cuacaaagggaagcccuuuc-3′ and 3′-uugauguuucc
cuucgggaaag-5′ (Fig. 1). A non-specific control miRNA
duplex was purchased from HSS (Sapporo, Japan), and
the scrambled sequence was 5′-gaguccgccucuauagacaa-3′.
Formation of the miRNA/atelocollagen complex
The miRNAs and atelocollagen complexes were pre-
pared according to the manufacturer’s instructions
(Koken Co.). Briefly, equal volumes of 1.0 % atelocolla-
gen [in phosphate-buffered saline (PBS) at pH 7.4] and
miRNA solution (in PBS) were combined and mixed by
rotation (4 rpm) at 4 °C for 20 min before centrifugation
(10,000 rpm) at 4 °C for 1 min. The complex was used
for inoculation into immunodeficient mice (KSN/Slc)
(Shimizu Laboratory Supplies Co., Ltd., Kyoto, Japan).
The final concentrations of atelocollagen for subcutaneous
injection, intraperitoneal injection or intravenous injection
in vivo were 10 μM, 40 μM or 0.5 %, respectively (Fig. 1).
Stability of the siRNA/atelocollagen complex
Aliquots of 0.9 mg of miRNA and 0.5 % atelocollagen
complexes were incubated in the presence of 0.1 mg/ml
RNase A (NipponGene, Tokyo, Japan) for 0, 5, 15, 30, 45
and 60 min at 37 °C. The solutions were then extracted
with phenol and phenol/chloroform/isoamyl alcohol
(25:24:1). The miRNAs were precipitated with ethanol,
separated by 3.5 % agarose gel electrophoresis and
visualized by ethidium bromide staining (Fig. 1).
Cell lines and immunodeficient mice
Two undifferentiated human cell lines, hepatoma cells
(HLF) and malignant melanoma cells that do not pro-
duce melanin (HMV-1) were obtained from Tohoku
University and the American Type Culture Collection
(ATCC), respectively. They were maintained in Roswell
Park Memorial Institute (RPMI) 1640 Medium (WAKO,
Tokyo, Japan) with 10 % heat-inactivated fetal bovine
serum (FBS) at 37 °C in a humidified atmosphere of 5 %
CO2. A total of 5 × 10
7 cells were harvested and inocu-
lated into mice subcutaneously, intraperitoneally or
intravenously using a 26-gauge needle. Six-week-old im-
munodeficient mice were inoculated for in vivo study by
miR-520d-5p transfection. Immunodeficient KSN/Slc
mice were used to examine the anti-metastatic effects of
miR-520d-5p or the transformation to normal status by
miR-520d-5p (Fig. 1). The athymic mice were anesthe-
tized by intraperitoneal injection of 100 mg/kg Nembu-
tal. All animals were housed and fed in the Division of
Laboratory Animal Science at Tottori University (Tottori,
Japan) under a protocol that was approved by the Japanese
Association for Accreditation for Laboratory Animal Care,
and animal research and handling were performed in
strict accordance with the federal Institutional Animal
Care and Use Committee guidelines. All experiments
reported in this study were approved by an institutional
committee (#13-Y-37, #18-2-41, #h27-074) and ARRIVE
guidelines have been followed.
In addition, the human mesangial cell line 293FT (Invi-
trogen Japan K.K., Tokyo, Japan) was used for producing
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GFP-expressing lentiviral particles. Briefly, 293FT cells were
cultured in DMEM supplemented with 10 % FBS, 0.1 mM
MEM non-essential amino acids solution, 2 mM L-glutamine
and 1 % penicillin/streptomycin.
Gene expression analysis by reverse transcription-
polymerase chain reaction (RT-PCR)
Total RNA, including the small RNA fraction, was ex-
tracted from cultured cells or from homogenized mouse
tissues with the mirVana miRNA Isolation Kit (Ambion,
Austin, TX, USA). Mature miRNA (miR-520d-5p, 25 ng/μl)
was quantified with the Mir-X™ miRNA qRT-PCR
SYBR® kit (Takara Bio, Tokyo, Japan) according to the
manufacturer’s instructions. The gels were run under
the same experimental conditions. PCR and data collec-
tion analyses were performed with a BioFlux LineGene
(Toyobo, Nagoya, Japan). To analyze the RT-PCR results,
all data were normalized to a β-actin internal control. U6
small nuclear RNA was also used as an internal control.
Total RNA (25 ng/μl) was reverse transcribed and ampli-
fied using the KAPA SYBR FAST One-Step qRT-PCR
Kit (Nippon Genetics Co, Ltd, Tokyo, Japan). RNA
quantification was confirmed by sequencing with high
reproducibility. Additional file 1: Table S1 presents the
primer sequences that were used for mRNA or miRNA
quantification. The data were analyzed statistically by one-
Fig. 1 Schematic of the study design and processes. Atelocollagen and miR-520d-5p were conjugated following the manufacturer’s instructions,
and the resulting complex was injected into immunodeficient mice that were inoculated with cancer cells. In addition, 520d-conjugated atelocollagen
was administered to mice via three different methods (see Methods for further details)
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way analysis of variance (ANOVA) or Mann-Whitney U
tests, and significant differences are shown as *P < 0.05
and **P < 0.01.
Cell migration assay
The invasive abilities of transfected cells were estimated
using a CIM-Plate 16, which detects cell invasion/migration
in real time following the manufacturer’s instructions
(xCELLigence system, Roche, Basel, Switzerland).
Immunocytochemistry
Immunohistochemical examination was performed with
antibodies to detect engraftment evidence (anti-hSIX1
and anti-hGFAP) following the manufacturer’s instruc-
tions (Atlas Antibodies AB, Stockholm, Sweden and
R&D Systems, Minneapolis, MN, USA, respectively).
HLF and HMV-I cells were infected with lentiviral parti-
cles that contained hsa-miR-520d-5p. Floating transfec-
tants were harvested and transferred to new culture
dishes for microscopic examination or slide chambers
for immunostaining.
Flow cytometry analysis
Cell cycle analyses were conducted to confirm that the
520d/HMV-I cells comprised benign cell populations, as
previously reported for 520d/HLF [27]. DNA content of
the cells was analyzed with a flow cytometer (Epics
Altra; Beckman Coulter Inc., CA, USA). Cells were
assessed by approximately 20,000 collected events after
the transfection of a pMIRNA1-miR-520d-5p/GFP clone
using EXPO32 ADC analysis software. GFP-positive cells
were sorted on a Moflo XDP cell sorter (Epics Altra;
Beckman Coulter Inc.). Specifically, for cell cycle ana-
lysis, a single cell suspension was washed once with cold
PBS. The cell pellet was loosened by shaking the tube
gently and was fixed with 3.7 % formalin in ddH2O,
which was added dropwise. The cells were then incu-
bated at least overnight at 22 °C. After fixation, the cells
were washed twice with cold PBS to remove the EtOH,
resuspended at 1 × 106 cells/ml in PBS with 100 U/ml
RNase A and incubated for 50 min at 37 °C. Next,
50 mg/ml of propidium iodide was added, and the mix-
ture was incubated for 40 min on ice in the dark. DNA
content was analyzed with a flow cytometer; the cells
were assessed by approximately 20,000 collected events
after the transfection of a pMIRNA1-miR-520d-5p/GFP
clone and prior to EXPO32 ADC analysis software.
miRNA transfer procedures in vivo
The miR-520d-5p/atelocollagen complex was injected
into immunodeficient mice topically, intraperitoneally or
systemically (Fig. 1). To identify the anti-cancer effects
of miR-520d, we examined its effects on two cell lines
(HLF or HMV-I) in vivo. Atelocollagen was used as a
carrier. The cells were subcutaneously inoculated into
the right flanks of the mice (n = 8 for each cell line), in-
traperitoneally into the center of the abdomen (n = 8) or
intravenously into the caudal vein (n = 8). Because
miRNA expression in tumors was evaluated after cat-
egorizing the parts of the tumor as described in our pre-
vious report [11], we started examining the therapeutic
effect when the tumor size was 8 mm (for HLF) or
5 mm (for HMV-I) in the subcutaneous xenograft model.
The miRNA/atelocollagen conjugates were administered
to 6-week-old mice every 7 days for approximately 90 days.
The observation period was a maximum of 6 months for
mice whose inoculated tumors disappeared. The animals
were sacrificed after 15 weeks (for HLF) or 12 weeks
(for HMV-I) and examined for gross tumor formation
and metastasis. Mice prepared for systemic delivery
received an intravenous injection every week, starting
1 week after the first injection of HLF or HMV-I cells.
The injection volume was 200 μl and contained 1 × 107
cells. Palpable tumors were confirmed on day 7 following
inoculation. Volume estimations were determined using
the following formula: volume = π/6 × width × length ×
height. After the mice were sacrificed, we assessed intra-
hepatic tumors, intraperitoneal dissemination, microme-
tastases in organs (brain, lung, heart, spleen, small
intestine, liver and kidney) and the presence or absence of
atelocollagen-associated adverse effects, such as intravas-
cular embolism. In the intraperitoneal xenograft model,
therapeutic injection was initiated 1 week after the inocu-
lation at the same concentration of 520d/atelocollagen as
of the subcutaneous injection. Via systemic administration
through the caudal vein, 0.5 % 520d/atelocollagen was
used 1 week later or earlier than the inoculation. Intratu-
moral gene expressions were estimated according to our
previously reported method [11].
Evaluation of miRNA transfer in vivo
RNA quantification was confirmed by sequencing with
high reproducibility. Tissues were subjected to miRNA
extraction using a mirVana miRNA Isolation kit, and
miRNA expression was examined using a Mir-X™
miRNA qRT-PCR SYBR kit to confirm suppression by
siRNA and to evaluate changes in miRNA expression
using the 2-ΔΔCt method according to the manufacturer’s
recommendations. Genes were chosen from those with
altered expression levels in response to miR-520d-5p
induction and silencing. Western blot analyses were
performed using the i-Blot gel transfer system (Life Tech-
nologies Japan, Tokyo, Japan). Antibodies [anti-p53, anti-
Nanog, anti-Oct4, and anti- activation-induced cytidine
deaminase (AICDA)] were diluted 1:500, and the control
anti-β-actin antibody was diluted 1:1000. Chemilumines-
cent signals were detected within 1 min using a LAS-4000
(Fujifilm, Tokyo, Japan).
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Analysis of miRNA delivery using in vivo imaging
Cells were subcutaneously injected (5 × 107 cells per site)
into athymic nude mice. When the tumors grew to 5 to
8 mm in size, atelocollagen alone, control miRNA conju-
gated with atelocollagen (scrambled), or 520d-5p/atelo-
collagen was injected around the tumors as described
previously [11]. Each group consisted of 8 animals. In
vivo bioimaging was conducted on a cryogenically
cooled IVIS system (Xenogen Corp., Waltham, MA,
USA) using LivingImage acquisition and analysis soft-
ware [29]. Tumor growth was monitored by measuring
the light emission from individual mice 21 to 28 days
after miRNA administration. Tumor growth was not
affected by these treatments.
Histological examination
Tumor nodules were investigated macroscopically or
under a dissecting microscope with bright-field imaging.
The tissue samples were fixed in 10 % buffered formalin
overnight, washed with PBS, transferred to 70 % ethanol,
embedded in paraffin, sectioned and stained with
hematoxylin-eosin (HE). GFP expression in tissues was
observed in unstained and HE-stained samples using an
EVOS FL cell imaging system (Life Technologies Japan,
Tokyo, Japan).
Lentiviral vector construct and reporter gene labeling of
tumor cells
To examine the effects of miR-520d-5p overexpression,
we transfected pMIRNA1-miR-520d-5p/GFP (20 mg;
System Biosciences, Mountain View, CA, USA) into
293FT cells (5 × 106 cells/10-cm culture dish). To har-
vest viral particles, the cells were centrifuged at 170,000
x g (120 min, 4 °C). The viral pellets were collected, and
viral copy numbers were measured with a Lenti-X™ qRT-
PCR Titration kit (Clontech, Mountain View, CA, USA).
For infection into HLF cells or HMV-I cells, 1 × 106
lentiviral copies were used per 10-cm culture dish. To
estimate the efficacy of infection by the GFP-expressing
lentiviral vector (pMIRNA1/GFP, 20 μg; System Biosci-
ences, Mountain View, CA, USA), GFP expression in
HLF or HMV-I cells was detected with the EVOS FL cell
imaging system. Transfectants without viral particles in
the culture supernatant were used for tumor formation
in vivo.
Quantitative Alu-PCR
Extraction of DNA from tumor tissues or injected sites
without tumors was performed using CellEase Tissue II
according to the manufacturer’s instructions (Biocosm
Inc., Tokyo, Japan). By quantitative Alu-PCR [30, 31],
the presence of human-derived genomic DNA in 50 ng
of DNA extracted from the injection site of mice was
examined (n = 4). The subcutaneous tumor disappeared
in all cases, and the scar-like, slightly protruding parts
were examined. Primer sequences were as follows: sense,
5′-GTCAGGAGATCGAGACCATCCC-3′; and anti-
sense, 5′-TCCTGCCTCAGCCTCCCAAG-3′. Thermal
cycling was conducted at 95 °C for 2 min (“hot start”),
followed by 35 cycles of 95 °C for 15 s, 68 °C for 30 s
and 72 °C for 30 s. Initial experiments varied the anneal-
ing and/or extension times and temperatures to optimize
the assay. A melt curve was also performed after the
assay to verify the specificity of the reaction. The melt
curve consisted of 20 s at 72 °C followed by a ramp up
of 1 °C steps with a 5-s hold at each step.
Immunohistochemical staining
Specimens were fixed in 4 % paraformaldehyde for 7 days.
Paraffin sectioning was conducted using a Young-type
sliding microtome (Sakura Finetek Japan, Co., Ltd.) with a
disposable microtome blade. Sections were approximately
3 μm in thickness and were mounted on silane-coated
slides. Immunohistochemical staining was performed ac-
cording to the labeled streptavidin-biotin (LSAB) method.
After the deparaffinized sections had been autoclaved at
120 °C for 10 min to block endogenous peroxidase activ-
ity, they were incubated sequentially at 4 °C for 1 h each
with anti-ZO-1 (Zymed) diluted to 1:100 in Tris-buffered
saline (TBS) and then in streptavidin-biotin-peroxidase
solution according to the instructions for the LSAB kit
(Dako Japan Co., Ltd.). The immunoreaction was visualized
with the peroxidase-diaminobenzidine (DAB) reaction.
Finally, the sections were counterstained with hematoxylin.
The stained sections were then observed with an Olympus
DP70 (Olympus, Japan) light microscope. The antibodies
(SIX1 and GFAP) were diluted at 1:500 for use.
Statistical analyses
The Mann-Whitney U-test was used for comparisons
between the controls, the scrambled and/or the miR-
520d-5p results with one observed variable. P-values
considered to indicate a significant difference were labeled
as follows: *, P < 0.05 and **, P < 0.01. In box plots, the top
and bottom of each box represent the 25th and 75th per-
centiles, respectively, thus providing the interquartile
range. The line through the box indicates the median, and
the error bars indicate the 5th and 95th percentiles.
Results
In vitro study in undifferentiated melanoma cells (HMV-I)
As we reported previously [27], HLF could be converted
to a benign or normal status by miR-520d-5p via a
stemness-mediated process. In the present study, we
assessed the tumor-suppressive effect of miR-520d-5p
on undifferentiated melanoma cells (HMV-I) in vitro
and attempted to examine the therapeutic effect of the
miRNA on two cell lines (HLF or HMV-I) using
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atelocollagen as a DDS carrier biomaterial. Although
miR-520d-5p completely penetrates all of the tumor cells
in tumor tissues, viable cells persist after its delivery. We
transfected HMV-I cells with 520d-5p using a lentiviral
vector in vitro (520d/HMV-I) and confirmed the forma-
tion of spheroid-like populations (Fig. 2a; top) that
expressed the GFP reporter gene (Fig. 2a; middle) and
the pluripotent marker Nanog (Fig. 2a; bottom). After
we confirmed miR-520d expression (Fig. 2b), DNA con-
tent, analyzed by flow cytometry, revealed a shift toward
homogeneous proliferation in the S phase, as described
for the HLF cells in our previous report [27] (Fig. 2c).
The 520d/HMV-I cells did not invade the fibronectin
membrane in a migration assay, as was observed for the
mock/HMV-I or HMV-I cells (Fig. 2d). A similar experi-
ment was performed in HLF cells [27].
In vivo study in two undifferentiated cells (HMV-I and HLF)
We performed an in vivo study using 520d-5p-conjugated
atelocollagen (520d/atelocollagen) to assess its topical
effects on cancer tissues after we confirmed intense GFP
expression in the two cell lines (Fig. 3a top, b top).
Although GFP expression was confirmed, the intensity of
expression was somewhat variable between cells (Fig. 3a, b
left bottom, respectively). After subcutaneously inoculat-
ing HLF (top) or HMV-I (bottom) into nude mice and
allowing the tumor to develop to 5 to 8 mm in size (corre-
sponding to the time of approximately 3–4 weeks after
inoculation), 520d/atelocollagen was injected into the
tumor once per week. The average fluorescence intensity
after subcutaneous injection of 520d/atelocollagen was
recorded and is depicted in Fig. 3a and b (bottom). This
analysis revealed that 62.5 % (5/8) of HLF tumors and
Fig. 2 Lenti-viral transfection of 520d-5p to HMV-I cells in vitro. a A representative phenotype of 520d/HMV-I is presented (x100 magnification).
Spheroid-like cells comprising a small fraction of the cell population are presented (top). Analysis of GFP expression confirmed the effective
induction (more than 99 %) of 520d/HMV-I cells (x100 magnification) (middle). miR-520d-5p induced the expression of Nanog in HMV-I
cells (x100 magnification) (bottom). The phenotypic changes were not sufficient to assess whether they were malignant or benign. b Significant
520d-5p expression was confirmed in 520d/HMV-I cells (*, P < 0.01 by the Mann-Whitney U test). The relative expression of 520d-5p in 520d/HMV-I cells
compared with mock/HMV-I cells is presented. All expression data are standardized to the β-actin expression level (n = 4). c Fluorescence activated cell
sorting (FACS) analysis revealed that GFP-positive 520d/HMV-I cells (right) exhibited increased DNA content in the S phase compared with GFP-positive
mock/HMV-I cells (left). d The invasive abilities of HMV-I, mock-transfected HMV-I (mock/HMV-I) and HMV-I cells treated with miR-520d-5p (520d/HMV-I)
were estimated with a migration assay using a fibronectin membrane (10 μg/ml). Most of the 520d/HMV-I cells did not pass through the membrane
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87.5 % (7/8) of HMV-I tumors were significantly sup-
pressed, whereas 37.5 % (3/8) of HLF tumors (Fig. 3c; top)
and 12.5 % (1/8) of HMV-I cells (Fig. 3c; bottom) disap-
peared. The tumors that eventually disappeared were
observed for 12 weeks. During that time and in the
absence of 520d/atelocollagen injections, we did not detect
any recurrent tumors (Additional file 2: Figure S5).
Among HLF tumors, the average suppression rates of
tumor size in the subcutaneous, intraperitoneal, and
systemic (metastasis) models were 92.7 %, 75.0 % (6/8)
and 100 % (8/8), respectively (Table 1). An average of
85.9 %, 87.5 % (7/8) or 100 % (8/8) of HMV-I tumors
exhibited tumor size suppression in the subcutaneous,
intraperitoneal, and metastasis models, respectively
(Table 1). The suppressive effect of miR-520d-5p on
subcutaneous tumors and metastasis was calculated based
on the data collected each week or the findings at the time
of sacrifice (Additional file 3: Table S2 or Additional file 4:
Table S3, respectively). However, when the animals were
sacrificed, most tumors grew increasingly, and the
suppressive effect of 520d-5p on tumor growth could not
be observed by RT-PCR (Additional file 5: Figure S6).
In vivo imaging using GFP expression in tumors
The therapeutic effect of 520d-5p on subcutaneously
inoculated tumors was evaluated based on the intensity
of the GFP signal using an in vivo imaging system.
Among the GFP-expressing HLF cells that received
520d-5p (520d/HLF/GFP), 37.5 % (3/8) exhibited a
gradual decrease in the signal, followed by disappearance
Fig. 3 An in vivo study to assess the topical effects of 520d-5p-conjugated atelocollagen on cancer tissues. a, b After we generated GFP-
expressing HLF (HLF/GFP) or HMV-I (HMV-I/GFP) cells using lentiviral constructs (top for each), the therapeutic effects of 520d/atelocollagen on the
resulting GFP-expressing tumors in mice were examined. The average fluorescence intensity in tumors was measured, and representative data are
presented through week 8 (bottom of each panel). GFP expression was maintained during the observation period in both studies. Dotted lines
indicate tumor growth in controls. c Overviews of the in vivo study using 520d/atelocollagen in a mouse xenograft model (top, HLF; bottom,
HMV-I). In the group that was administered the 520d/atelocollagen complex, tumor volume was significantly suppressed relative to the control
group. *, P < 0.01 by the Mann-Whitney U test. The tumor volume of HLF cells from 11 to 15 weeks or of HMV-I cells from 9 to 12 weeks was
analyzed and compared with control or scrambled data at 10 weeks or 8 weeks, respectively. The arrow indicates the timing of the doses that
were administered to each group from 3 to 9 weeks (c) and from 3 to 7 weeks (d). ↓: injection of complex (once a week);▲: atelocollagen alone;
●: scramble/atelocollagen; ■: miR-520d-5p/atelocollagen (cases with suppressive growth); □: miR-520d-5p/atelocollagen (cases with tumor disappearance);
✝: mice were sacrificed; CI: confidence interval
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of the signal in the 5th week (representative data are
shown in Fig. 4a top), whereas GFP-expressing HLF cells
that received a scrambled construct (scrambled/HLF/
GFP) exhibited an increase in the GFP signal accompan-
ied by gradual growth (representative data are shown in
Fig. 4a bottom). Among GFP-expressing HMV-I cells
that received 520d-5p (520d/HMV-I/GFP), 12.5 % (1/8)
exhibited a gradual decrease in the GFP signal followed
by its disappearance in the 5th week (representative data
are shown in Fig. 4b top), whereas GFP-expressing
HMV-I cells that received the scrambled construct
(scrambled/HMV-I/GFP) exhibited an increase in GFP
signal accompanied by gradual growth (representative
data are shown in Fig. 4b bottom).
Evaluation of tumor suppression by histological and
molecular examination
Histological changes at the injection sites and in main
organs, including vessels, were examined after resection.
Although the tumors that were resected at the end of the
observation period no longer demonstrated suppressed
growth, we examined the expression level of miR-520d-5p
in the resected tumors. HMV-I tumors that received
520d-5p weekly for 12 weeks exhibited significantly upreg-
ulated 520d-5p, and HLF tumors that received 520d-5p
weekly for 15 weeks tended to upregulate 520d-5p
(Fig. 5a). Intratumor upregulation of 520d-5p was con-
firmed, but the expression levels of P53 and pluripotent
markers observed in vitro were not altered relative to
those in parental or scramble-transfected cells when mice
were sacrificed (Additional file 6: Figure S1). HLF tumors
treated with 520d/atelocollagen exhibited GFP-expressing
muscle tissues, including an undifferentiated tumor that
was unaccompanied by necrosis (Fig. 5b; left). In contrast,
HMV-I tumors treated with 520d/atelocollagen exhibited
an undifferentiated tumor accompanied by extensive
necrosis (Fig. 5b; right). Approximately 0.5 mm3 of pro-
truding tissue that resembled a scar at the injection site of
HLF cells did not contain any malignant cells but was con-
firmed to be the mouse muscle subjected to the injection
(Fig. 5c; top left). Interestingly, this tissue expressed GFP
(Fig. 5c; bottom left). Similarly, non-tumorous tissue at
the injected site of HMV-I cells did not contain any
malignant cells and was histologically diagnosed as normal
murine tissue (Fig. 5c; top right) but did express GFP
(Fig. 5c; bottom right). In addition, adverse effects and
toxicity were assessed in this study. For the period of
6 months when the mice or tumor-inoculated mice were
observed, their normal activities were maintained without
weight loss or anorexia. The mice did not experience any
toxic reaction (such as embolism) in response to the
infusion of atelocollagen (Additional file 7: Figure S2).
Presence of human genome and gene expression at
injection site of mice
By quantitative real-time Alu-PCR, we detected an average
of 55.0 pg of human-derived genomic DNA in 50 ng of
DNA extracted from the injection site of the mouse (Fig. 5d).
This finding was usually observed in all cases in which
tumors disappeared (for a case of glioblastoma, see
Additional file 8: Figure S3). The site where HMV-I cells
were injected and where the tumor disappeared included
approximately 0.1 % human tumor cell-derived DNA in
murine DNA. Alu-PCR using DNA from each organ of the
mice that received intravenous injections was not successful.
Immunohistochemistry revealed that murine normal
subcutaneous regions (Fig. 6, upper) or the scar-like
protruding region (Fig. 6, middle) at the injection site
included human muscle-derived gene expression (SIX1).
Discussion
Drug delivery carriers using RNA-based medicine have
undergone repeated improvements. There is an urgent
need to develop new formulations or to optimize the
modification of the molecules themselves to overcome
the instability of RNA molecules when they are used in
biological techniques or employed for in vivo studies to
evaluate their usefulness [32–34].
Increasing evidence has suggested that miRNAs are
strongly associated with numerous biological processes,
including oncogenesis or tumor progression [35–37]. Im-
provements in nanoparticles [38], cationic polymer [39],
antisense [32] or mimic RNA [40, 41], viruses [13], and
artificial viruses [42] have been intensely pursued to
increase quality. Atelocollagen is also a DDS carrier that is
used topically in cosmetics and in plastic and reconstruct-
ive surgery. This biomaterial is now experiencing
expanded use for intraperitoneal or systemic administra-
tion and for subcutaneous injection in cancer therapy
[23, 43–46].
Table 1 Summary of therapeutic effect miR-520d-5p/Atelocollagen complex in a xenografted model
Cancer cells Tumor suppressive effect in
subcutaneous model (n = 8 for each)
10 week, average%
Therapeutic effect in peritoneal
model (n = 8 for each)
% (effective/total)
Metastasis suppressive effect
in caudal vein model
(n = 8 for each) % (effective/total)
HLF (undifferentiated hepatoma) 92.7 75.0 (6/8) 100 (8/8)
HMV-1 (undifferentiated melanoma) 85.9 87.5 (7/8) 100 (8/8)
effective/total: the number of mice with tumor disapperance/total number of examined mice
10 week, average%: average of tumor suppressive rate each week compared with control during 10 week obsevation (see Additional file 7: Figure S2)
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In this study, we first attempted to examine the tumor
suppressive effect of miR-520d-5p using atelocollagen
with subcutaneous injection. Because this DDS carrier
could not penetrate into all cancer cells and left viable
cancer cells in tumor tissues, it allowed the tumor to
grow gradually, indicating that an assay system must be
established to optimize the injection conditions. It was
reported previously that atelocollagen accumulates in
prostate cancer cells (PC-3) [47]. However, when 520d/
atelocollagen was injected into subcutaneous tumors,
Fig. 4 The therapeutic effect of 520d-5p-conjugated atelocollagen on subcutaneously inoculated tumors as monitored by an in vivo imaging
system. a A representative image of the therapeutic effect of 520d-5p/atelocollagen using an in vivo imaging system. At each inoculation site,
37.5 % (3/8) of the tumors disappeared. The growth of tumors that received 520d-5p was significantly suppressed, and metastatic ability was
entirely inhibited in the remaining mice. A time course (top) of 520d/HLF/GFP cells (520d-5p-transfected and GFP-expressing HLF) is depicted.
Representative sequential images (bottom) of scrambled/HLF/GFP cells (scrambled-transfected GFP-expressing HLF). b In HMV-I tumors, 12.5 %
(1/8) of the tumors disappeared. After treatment with 520d-5p, the growth of other tumors was significantly suppressed, and their metastatic
ability was entirely inhibited. 520d/HMV-I/GFP and scrambled/HMV-I/GFP indicate 520d-5p-transfected, GFP-expressing HLF (top) and scramble-
transfected, GFP-expressing HMV-I (bottom), respectively
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the tumor size did not exceed 8 mm for the cells used in
this study (HLF and HMV-I), and tumor growth was
significantly suppressed each week. Upregulation of p53
and Nanog and downregulation of AICDA were ob-
served, similar to observations for other undifferentiated
cancer cells, e.g., glioblastoma, pancreatic cancer and
anaplastic thyroid cancer. The in vitro study could not
significantly confirm intratumoral expression after sacri-
fice compared with parental or scrambled-transfected
cells. Although a considerable number of mice did not
develop any tumor nodules, the greatest effect of 520d/
atelocollagen was the suppression of metastasis. When
520d/atelocollagen was injected around the tumor rather
than intratumorally, mice in which a tumor-inhibiting
effect was observed did not display any (micro) metasta-
ses, even in the tissues surrounding the tumor. The
inoculation of 520d-5p-expressing HMV-I (520d/HMV-I)
resulted in the suppression of tumor formation in 33.3 %
of mice (3/9), and metastasis was inhibited in 100 %
(9/9) of mice (Additional file 9: Table S4). We cannot
exclude the possibility that mouse cells and human
cells may co-exist in the mouse tissue without evi-
dence of rejection. A similar phenomenon may exist
in 520d-expressing human glioblastoma (T98G) cells
that were intracranially injected into the thalamus, result-
ing in the co-existence of human-derived cancer cells as
endothelial cells and glial cells (i.e., normal human cells)
in the brain tissue of mice who received injection without
generating a malignant brain tumor (Additional file 8:
Figure S3). Furthermore, we examined the transcriptional
expression levels of BRAF, PDCD1 and PDCD1 LG2 to
investigate their correlation with gene expression. As a
selective BRAF inhibitor, vemurafenib is used for pa-
tients with malignant melanoma [47]. BRAF tended
to be downregulated by 520d-5p (P = 0.05 by the
Mann-Whitney U test) (Additional file 10: Figure S4).
Fig. 5 Evidence of human genomic DNA at the injection site. a miR-520d-5p expression was examined in HLF (n = 5) and HMV-I (n = 7) tumors
resected after 520d/atelocollagen treatment. 520d/HMV-I tumors significantly expressed 520d-5p (*, P < 0.05), and 520d/HLF tumors tended to
express miR-520d-5p (P = 0.051). scram.: scrambled. b Microscopic examination of HLF (left; HE stain, x100 magnification) and HMV-I tumors (right;
HE stain, x200 magnification) that displayed suppressed tumor growth. HLF tumors treated with 520d/atelocollagen exhibited GFP-expressing
muscle tissues, including undifferentiated tumor cells unaccompanied by necrosis. HMV-I tumors treated with 520d/atelocollagen showed undifferentiated
neoplastic cells. This finding is not inconsistent, as malignant melanomas are observed to be accompanied by extensive necrosis, as shown
around A. c Histological findings in the area where there should have been a tumor are presented (HE stain, x40 magnification). The area of
the HLF tumors that disappeared is surrounded by an oval (left top). GFP expression was confirmed (left bottom). Histological findings in the
disappearance site of HMV-I tumors showed no malignant cells. This finding was similar to that for 520d-treated HLF tumors (HE stain, x200
magnification) (right top), but we observed GFP even in the connective tissue (right bottom). We did not observe any malignant cells in the
injection sites of mice in either case. d Fluorescence (F) (top) and a quantitative calibration line (bottom) in quantitative Alu-PCR. P.C. (left arrow)
indicates a representative positive control (a subcutaneous tumor generated from mock/HLF cells). The reaction of interest was performed using DNA
from the scar-like area of cases (C; right arrow) to confirm that human genomic material was present in the injection site. The average amount of
human genomic DNA derived from human hepatoma (mock/HLF: n = 3) was approximately 50 ng. Case (C) showed 55.0 pg. The genome copy
number was calculated based on the fact that 1 pg corresponds to approximately 0.333 human genome copies. Correlation coefficient, r = −0.996
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In addition, 520d-5p may have other anti-cancer ef-
fects on BRAF-related genes, except for the conver-
sion of transfectants to a more immature status.
Atelocollagen prevents immune-stimulatory adverse
effects [48], and 520d-5p suppresses immunoreaction by
downregulating AICDA [27]. These properties may be
involved in the phenomenon observed in this study.
Thus, miR-520d may be an interesting molecule whose
mechanism should be clarified.
We postulate that a possible mechanism underlying
tumor-suppressing effect by 520d-5p can be TP53 upreg-
ulation induced by downregulation of MYST1 which is
implicated in methylation process [49]. Because MYST1
are indirectly downregulated by 520d-5p upregulation,
we are attempting to prove the detail mechanisms.
Thus, 520d/atelocollagen may be a potent candidate
therapeutic agent with anti-metastatic effects [50]. Be-
cause the efficiency of the introduction of such conjugat-
ing materials into a target cell or target tissue remains
unclear, further careful investigation is needed before the
application of this therapy in humans.
Conclusions
To our knowledge, this study provides the first evidence
that the 520d-5p/atelocollagen vehicle is a useful biomaterial
for in vivo xenograft studies or for clinical use as an anti-
cancer therapy.
Additional files
Additional file 1: Table S1. The sequences of primers used in this
study. Primers used in this study are presented. (PDF 69 kb)
Additional file 2: Figure S5. A representative case 24 weeks after
subcutaneous injection. A pathologist recognized adipose tissue and
skeletal muscle thought to be the existing structure but could not
confirm the clear tumor composition at the injection site (HE stain; top
left, the perspective of the specimen; bottom, x40, x100 magnification).
We did not identify any macroscopic tumors in this case. (PDF 341 kb)
Additional file 3: Table S2. The suppression rate (%) of tumor volume.
The suppression rate (%) of tumor volume compared with the control
each week is shown in Table 1. Greater than 85 % suppression 6 weeks
after administration was observed in a xenograft model by subcutaneous
injection. (PDF 92 kb)
Additional file 4: Table S3. Effective rate of tumor disappearance.
Effective rate (%) of tumor disappearance by systemic administration
compared with that of the control is shown in Table 1. Greater than 75 %
of the tumor cells disappeared based on macroscopic and microscopic
observation. (PDF 94 kb)
Additional file 5: Figure S6. Representative gene expression in HMV-I
tumors without suppression. When the animals were sacrificed, most
tumors grew increasingly and the suppressive effect of 520d-5p on tumor
growth could not be observed by RT-PCR. *: P < 0.05 by Man-Whitney
U test. (PDF 267 kb)
Additional file 6: Figure S1. A representative gene expression profile
of 520d/HMV-I. Upregulation of p53 and Nanog and downregulation of
AICDA were observed in 520d/HMV-I cells in vitro, similar to the results
for 520d/HLF cells. *, P < 0.05 by one-way ANOVA. Oct4 was not significantly
upregulated, but it was weakly upregulated, as indicated by western
blotting. (PDF 81 kb)
Additional file 7: Figure S2. The side effects of 520d/atelocollagen and
the presence of tumor cells in the inoculated tumor in seven organs.
Fig. 6 Pathological findings of human muscle-derived gene expression at the injection site. Immunohistochemistry showing human muscle-derived
gene expression (SIX1) in 3 normal subcutaneous regions (upper) and the scar-like, slightly protruding region (middle). The human muscular region in
subcutaneous tissue (bottom left) and the murine subcutaneous region (bottom right), including muscle, were used as a positive control and a negative
control, respectively. Scar-like formation (HE stain; middle left) induced by injection retained GFP expression (middle center) and weak human SIX1
expression in murine tissue (middle right). The representative region for immunostaining is denoted by a rectangle (top left), and arrows denote
moderate human SIX1 expression. The arrow shows the murine muscle region without human SIX1 staining (bottom left)
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Neither the presence of embolism induced by atelocollagen or evidence
of micrometastases was detected pathologically in brain, liver, spleen,
heart, lung, small intestine and kidney. (PDF 185 kb)
Additional file 8: Figure S3. An in vivo study using glioblastoma cells
(T98G) treated with miR-520d-5p (520d/T98G). Three surviving mice were
examined for human-derived gene expression in murine brain tissue
3 months after intracranial injection. a KSN/Slc mice were anesthetized
with sodium pentobarbital (50 mg/kg intraperitoneally) and placed in a
stereotaxic apparatus. During surgery, the animals’ body temperature was
maintained at 37 °C using a heating pad. The skull was exposed, and a
small craniotomy was made over the left striatum. A 30-gauge injection
needle connected to a 10-μl Hamilton syringe through polyethylene
tubing was used for 520d/T98G cell transplantation. The injection needle
was inserted stereotaxically into the left striatum (A 2.0 mm, L 0.5 mm, D
1.2 mm from bregma) (left), and 1 μl of cell suspension (1 × 108 cells/μl)
was pressure-injected (right). After injection, the needle was slowly with-
drawn, and the skull hole was covered with dental cement. The incision was
sutured with 6-0 Prolene. After recovery from surgery, the animals were
returned to their home cage. b Immunohistochemistry was performed
using anti-hGFAP antibody, and human-derived GFAP protein expression
was confirmed in glial cells and vascular endothelial cells in the murine
thalamus (left to right: x40, x200, x400 magnification). (PDF 203 kb)
Additional file 9: Table S4. Subcutaneous changes of 520d-5p-
expressing HMV-I in a xenograft model. Subcutaneous changes of
520d-5p-expressing HMV-I in a xenograft model were recorded as
criteria for tumor formation and metastasis. In HMV-I, the disappearance rate
of tumors was greater than the outcome (12.5 %) of therapeutic
administration in vivo. (PDF 32 kb)
Additional file 10: Figure S4. Relative mRNA expression levels of BRAF,
PDCD1 and PDCD1LG2, standardized to β-actin in HMV-I cells. A box plot
was drawn to compare expression levels. BRAF was not significantly
downregulated in 520d/HMV-I cells compared with mock/HMV-I cells
(by Mann-Whitney U test, n = 3), but it tended to be downregulated by
520d-5p. *, P < 0.05. (PDF 89 kb)
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